APA (7th ed.) Citation

Gonzalez-Bocco, I. H., Beluch, K., Cho, A., Lahoud, C., Reyes, F. A., Moshovitis, D. G., . . . Koo, S. (2023). Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity. Pilot & Feasibility Studies, 9(1), 1. https://doi.org/10.1186/s40814-023-01325-y

Chicago Style (17th ed.) Citation

Gonzalez-Bocco, Isabel H., et al. "Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals with Impaired SARS-CoV-2 Humoral Immunity." Pilot & Feasibility Studies 9, no. 1 (2023): 1. https://doi.org/10.1186/s40814-023-01325-y.

MLA (9th ed.) Citation

Gonzalez-Bocco, Isabel H., et al. "Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals with Impaired SARS-CoV-2 Humoral Immunity." Pilot & Feasibility Studies, vol. 9, no. 1, 2023, p. 1, https://doi.org/10.1186/s40814-023-01325-y.